shareholder movement update, page-25

Hi Dak

The paragraph requiring clarification is:

" Cellmid has extended its out-licensing program in relation to its midkine cancer diagnostic assets. Current licensees (Celera/Quest and Pacific Edge Biotechnology) have confirmed that they are continuing with their product
development programs including midkine as one of their cancer biomarkers."

I read it as meaning that the program has been extended (in scope) rather the the duration of some non-exclusive licences, for which up front fees have been paid and royalies upon commercialisation will become due.

One for Maria I guess.

There relevant Patent application number is 20090176228 The application includes the use of many proteins that are not in the final selection for the non smoker assay.

My understanding is that the tests are at the fine tuning phase which will will preceed the FDA application. There could be two goals here ..... firstly could ??? be to align the test mechanism with Quest's clinical capacity. The Celera/Quest test as it stood utilised a novel mass spectronomy approach. Having selected 6 biomarkers, I know not what Quest's preferred test platform will be. A second goal (is always) to ensure sufficient information to expediate the FDA approval process which I have read should be under 90 days (if there are no further questions) for in-vitero "medical device" diagnostic tests such as this one. Of relevance or not, Quest's test for smokers (that does not utilise midkine) is at the fine tuning stage proior to an expeced FDA application this year. My guess work can of course be VERY wrong BUT it does sort of align to previously CDY timeframe guestimates as announced some years back.

Cheers